Wong S - Search Results

1

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.

Jones L, Rittberg R, Leung B, Shokoohi A, Pender A, Wong S, Al-Hashami Z, Wang Y, Ho C. Jones L, et al. Among authors: wong s. Curr Oncol. 2022 Nov 15;29(11):8686-8692. doi: 10.3390/curroncol29110685. Curr Oncol. 2022. PMID: 36421338 Free PMC article.

2

Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype.

Naso JR, Wang G, Pender A, Wong SK, Zhu J, Ho C, Ionescu DN, Zhou C. Naso JR, et al. Histopathology. 2020 Feb;76(3):394-403. doi: 10.1111/his.13983. Epub 2019 Dec 23. Histopathology. 2020. PMID: 31454429

3

Canadian Lung Cancer Conference 2019.

Pender A, Dunne EM, Wong SK, Ho C, Melosky B. Pender A, et al. Among authors: wong sk. Curr Oncol. 2019 Aug;26(4):e578-e580. doi: 10.3747/co.26.5105. Epub 2019 Aug 1. Curr Oncol. 2019. PMID: 31548828 Free PMC article.

4

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes.

Pender A, Hughesman C, Law E, Kristanti A, McNeil K, Wong S, Tucker T, Bosdet I, Young S, Laskin J, Karsan A, Yip S, Ho C. Pender A, et al. Among authors: wong s. Transl Lung Cancer Res. 2020 Aug;9(4):1084-1092. doi: 10.21037/tlcr-19-581. Transl Lung Cancer Res. 2020. PMID: 32953487 Free PMC article.

5

Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.

Wong SK, Hamm J, Shokoohi A, McGahan CE, Ho C. Wong SK, et al. BMC Cancer. 2021 Mar 2;21(1):215. doi: 10.1186/s12885-021-07923-4. BMC Cancer. 2021. PMID: 33653306 Free PMC article.

6

MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.

Wong SK, Alex D, Bosdet I, Hughesman C, Karsan A, Yip S, Ho C. Wong SK, et al. Lung Cancer. 2021 Apr;154:142-145. doi: 10.1016/j.lungcan.2021.02.030. Epub 2021 Feb 24. Lung Cancer. 2021. PMID: 33667719

7

Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.

Shokoohi A, Al-Hashami Z, Moore S, Pender A, Wong SK, Wang Y, Leung B, Wu J, Ho C. Shokoohi A, et al. Among authors: wong sk. Cancer Med. 2022 Jan;11(1):86-93. doi: 10.1002/cam4.4427. Epub 2021 Nov 16. Cancer Med. 2022. PMID: 34786889 Free PMC article.

8

Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.

Wong SK, Gondara L, Gill S. Wong SK, et al. Curr Oncol. 2021 Nov 16;28(6):4748-4755. doi: 10.3390/curroncol28060400. Curr Oncol. 2021. PMID: 34898584 Free PMC article.

9

End-of-Life Health Resource Utilization for Limited English-Proficient Patients With Advanced Non-Small-Cell Lung Cancer.

Leung B, Wong SK, Ho C. Leung B, et al. JCO Oncol Pract. 2022 Oct;18(10):e1716-e1724. doi: 10.1200/OP.22.00110. Epub 2022 Sep 6. JCO Oncol Pract. 2022. PMID: 36067447

10

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.

Rittberg R, Leung B, Shokoohi A, Pender A, Wong S, Al-Hashami Z, Wang Y, Ho C. Rittberg R, et al. Among authors: wong s. Curr Oncol. 2023 May 26;30(6):5299-5308. doi: 10.3390/curroncol30060402. Curr Oncol. 2023. PMID: 37366885 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,381 results

Search Page

Filters